CUE BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 USD | +4.03% |
|
-9.55% | -46.21% |
| Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 | |
| Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
Presentation Operator MessageOperator (Operator)Greetings and welcome to the Cue Biopharma Inv...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.42
USD
Average target price
9.4
USD
Spread / Average Target
+561.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.21% | 69.07M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +2.59% | 22.18B | |
| -16.67% | 21.2B | |
| -9.19% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- CUE Stock
- News Cue Biopharma, Inc.
- Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
